-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

Benzinga·05/14/2026 13:17:47
Listen to the news
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $7 to $6.